| Objects: To assess the effect and safety of chuanxiong compounds inthe preventing acute stroke.Methods: This systematic review was guided by the CochraneReviewer's Handbook and the advice of the Cochrane Stroke Group. Wesearched the Cochrane Central Register of Controlled Trials in the CochraneLibrary (Issue 4, 2006), MEDLINE (1966 to 2006), EMBASE (1980 to 2006),the Chinese Biomedical Database (1979 to August 2006), VIP ChineseScience and Technique Journals Database (1989 to 2007), and ChinaNational Infrastructure (CNKI) (1979 to 2007). According to thepre-determined inclusion criteria, randomized controlled clinical trials areincluded. We analyzed the data of the outcome measures of the inclusiontrials.Results: The search identified two randomized controlled clinical trialsincluded totally 5293 patients. Meta-analysis was not performed since therewas great heterogeneity from the intervention and follow-up duration. In onetrial (Zhou 1999), comparing to control the risk factors, incidence [OR=0.23,95%CI(0.22, 0.47)] and mortality [OR=0.13, 95%CI(0.08, 0.39)] of strokewas lower in intervention group which were additionally administeredChuanxiong preparation; blood pressure [at the termination of the follow-up,systolic pressure: male WMD=-2.10, 95%CI(-2.20, -2.00), female WMD=-1.42, 95%CI(-1.48, -1.36); diastolic pressure female WMD=1.29,95%CI(1.26, 1.33), but no significant improvement in male WMD=0.00,95%CI(-0.06, 0.06)] and blood sugar [male WMD=0.37, 95%CI(0.34, 0.40),female WMD=0.44, 95%CI(0.41, 0.47)] was significantly improved inintervention group, the same improvement was observed regarding bloodlipid and cerebral vascular hemodynamic indices. In the other trial (Wang2003b), comparing to Chuanxiong preparation, it was noted that Chuanxiongcompound preparation was able to better improve the incidence [OR=0.40,95%CI(0.33, 0.68)] and mortality [OR=0.27, 95%CI(0.13, 0.67)] of stroke,blood pressure[systolic pressure WMD=-12.04, 95%CI(-15.04, -9.04),diastolic pressure WMD=-4.12, 95%CI(-5.87, -2.37)], blood sugar[WMD=-8.74, 95%CI(-13.84, -3.64)] and cerebral vascular hemodynamicindices[Qmean: left WMD=1.17, 95%CI(0.96, 1.38), right WMD=1.27,95%CI(1.07, 1.47); Vmean left WMD=4.60, 95%CI(3.97, 5.23), rightWMD=4.62, 95%CI(4.16, 5.08); Vmax left WMD=8.32, 95%CI(7.15, 9.49),right WMD=9.18, 95%CI(8.06, 10.30); Vmin left WMD=2.98, 95%CI(2.71,3.25), right WMD=2.91, 95%CI(2.67, 3.15); RV left WMD=-29.21,95%CI(-31.33, -27.09), right WMD=-36.49, 95%CI(-38.78, -34.20); Zcv leftWMD=2.58, 95%CI(2.11, 3.05), right WMD=2.80, 95%CI(2.21, 3.39)]; butno significance between two groups in serum cholesterol [WMD=3.60,95%CI(-1.60, 8.83)] and serum triglyceride [WMD=0.72, 95%CI(-9.26,10.70)]. No serious adverse events were reported.Conclusion: Only two randomized controlled clinical trials wereincluded, and we can not perform a meta-analysis. The results of the twotrials tended to prove that regarding to improvement of incidence andmortality of stroke and of relative indices, additionally administeredChuanxiong preparation was benefit as compared to singly interveneunderlying condition; and Chuanxiong compound preparation was more powerful than Chuanxiong alone. But evidence to support the conclusion isinsufficient. High quality clinical randomized controlled trials should becarried out.
|
PDF Full Text Request